{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:43:26Z","timestamp":1791110606558,"version":"4.1.0"},"reference-count":155,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1097\/maj.0b013e3180318fbc","type":"journal-article","created":{"date-parts":[[2007,3,30]],"date-time":"2007-03-30T09:08:44Z","timestamp":1175245724000},"page":"399-413","source":"Crossref","is-referenced-by-count":105,"title":["TUMOR NECROSIS FACTOR ANTAGONISTS"],"prefix":"10.1097","volume":"27","author":[{"given":"PANAGIOTIS G.","family":"THEODOSSIADIS","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NIKOLAOS N.","family":"MARKOMICHELAKIS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PETROS P.","family":"SFIKAKIS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20210130","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1056\/NEJM199606273342607","article-title":"The tumor necrosis factor ligand and receptor families.","volume":"334","author":"Bazzoni","year":"1996","journal-title":"N Engl J Med"},{"key":"R2-1-20210130","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1146\/annurev.immunol.19.1.163","article-title":"Anti-TNF-a therapy of rheumatoid arthritis: what have we learned?","volume":"19","author":"Feldmann","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"R3-1-20210130","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/00002281-200307000-00003","article-title":"TNF biology in experimental and clinical arthritis.","volume":"15","author":"Sfikakis","year":"2003","journal-title":"Curr Opin Rheumatol"},{"key":"R4-1-20210130","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1002\/j.1460-2075.1991.tb04978.x","article-title":"Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis.","volume":"10","author":"Keffer","year":"1991","journal-title":"EMBO J"},{"key":"R5-1-20210130","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1186\/ar1028","article-title":"Attenuation of inflammatory polyarthritis in TNF transgenic mice by diacerein: comparative analysis with dexamethasone, methotrexate and anti-TNF protocols.","volume":"6","author":"Douni","year":"2004","journal-title":"Arthritis Res Therapy"},{"key":"R6-1-20210130","first-page":"Siv2","article-title":"Updated consensus statement on biological agents, specifically TNFalpha blocking agents and interleukin-1 receptor antagonist (IL-r1a) for the treatment of rheumatic diseases, 2005 Ann Rheum D","volume":"64","author":"Furst","year":"2005","journal-title":"is"},{"key":"R7-1-20210130","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1136\/ard.2004.024737","article-title":"Anti-tumour necrosis factor \u03b1 therapy in rheumatoid arthritis: an update on safety.","volume":"63","author":"Hyrich","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"R8-1-20210130","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1093\/rheumatology\/keh617","article-title":"Safety of biologic therapies. An update.","volume":"32","author":"Keystone","year":"2005","journal-title":"J Rheumatol"},{"key":"R9-1-20210130","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/art.10308","article-title":"Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes.","volume":"46","author":"Genovese","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R10-1-20210130","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1186\/ar997","article-title":"Effective use of TNF antagonists.","volume":"6","author":"Yocum","year":"2004","journal-title":"Arthritis Res Ther"},{"key":"R11-1-20210130","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/rheumatology\/keh205","article-title":"Biological therapies in the spondyloarthritides: the current state.","volume":"43","author":"Braun","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"R12-1-20210130","doi-asserted-by":"crossref","first-page":"Sii78","DOI":"10.1136\/ard.2004.034157","article-title":"Psoriatic arthritis treatment: biological response modifiers.","volume":"64","author":"Mease","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R13-1-20210130","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa030409","article-title":"Etanercept as monotherapy in patients with psoriasis.","volume":"349","author":"Leonardi","year":"2003","journal-title":"N Engl J Med"},{"key":"R14-1-20210130","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2004.02.021","article-title":"Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial.","volume":"51","author":"Gottlieb","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"R15-1-20210130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s003840100285","article-title":"Use of anti-TNF agents in inflammatory bowel disease. European guidelines for 2001\u20132003.","volume":"16","author":"Schreiber","year":"2001","journal-title":"Int J Colorectal Dis"},{"key":"R16-1-20210130","first-page":"CD003574","article-title":"Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease.","author":"Akobeng","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"R17-1-20210130","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"R18-1-20210130","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000055677","article-title":"Aqueous humor and serum tumor necrosis factor-a in clinical uveitis.","volume":"33","author":"Lacomba","year":"2001","journal-title":"Ophthalmic Res"},{"key":"R19-1-20210130","first-page":"369","article-title":"Advances in Ocular Immunology. International Congress Series.","author":"Rahi","year":"1994"},{"issue":"Suppl 11","key":"R20-1-20210130","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-3083.1992.tb01645.x","article-title":"Ocular and systemic determination of IL-1 beta and tumour necrosis factor in a patient with ocular inflammation.","author":"Palexas","year":"1992","journal-title":"Scand J Immunol"},{"key":"R21-1-20210130","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(01)05497-6","article-title":"Effect of infliximab on sight-threatening panuveitis in Behcet's disease.","volume":"358","author":"Sfikakis","year":"2001","journal-title":"Lancet"},{"key":"R22-1-20210130","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.ajo.2004.12.009","article-title":"Improving the reporting of clinical case series.","volume":"139","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"R23-1-20210130","first-page":"3131","article-title":"Proctor Lecture. Experimental autoimmune uveitis: mechanisms of disease and clinical therapeutic indications.","volume":"32","author":"Nussenblatt","year":"1991","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R24-1-20210130","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/eye.1992.93","article-title":"Duke-Elder Lecture: New concepts on the role of autoimmunity in the pathogenesis of uveitis.","volume":"6","author":"Forrester","year":"1992","journal-title":"Eye"},{"key":"R25-1-20210130","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop.","volume":"140","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"R26-1-20210130","first-page":"3884","article-title":"The role of tumor necrosis factor-alpha in the induction of experimental autoimmune uveoretinitis in mice.","volume":"35","author":"Nakamura","year":"1994","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R27-1-20210130","doi-asserted-by":"crossref","first-page":"928","DOI":"10.4049\/jimmunol.136.3.928","article-title":"T cell lines mediating experimental autoimmune uveoretinitis (EAU) in the rat.","volume":"136","author":"Caspi","year":"1986","journal-title":"J Immunol"},{"key":"R28-1-20210130","first-page":"2211","article-title":"Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming.","volume":"37","author":"Sartani","year":"1996","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R29-1-20210130","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.4049\/jimmunol.168.5.2483","article-title":"Inflammatory mediators in uveitis: differential induction of cytokines and chemokines in Th-1-versus Th-2-mediated ocular inflammation.","volume":"168","author":"Foxman","year":"2002","journal-title":"J Immunol"},{"key":"R30-1-20210130","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1167\/iovs.02-1156","article-title":"Neutralizing tumor necrosis factor-a activity suppresses activation of infiltrating macrophages in experimental autoimmune uveoretinitis.","volume":"44","author":"Robertson","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R31-1-20210130","doi-asserted-by":"crossref","first-page":"5997","DOI":"10.4049\/jimmunol.158.12.5997","article-title":"IFN-gamma-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response.","volume":"158","author":"Jones","year":"1997","journal-title":"J Immunol"},{"key":"R32-1-20210130","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/BF00915816","article-title":"Ocular inflammatory effects of intravitreally injected tumor necrosis factor and endotoxin.","volume":"14","author":"Fleisher","year":"1990","journal-title":"Inflammation"},{"key":"R33-1-20210130","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0014-4835(88)80019-8","article-title":"Cachectin: a novel polypeptide induces uveitis in the rabbit eye.","volume":"46","author":"Kulkani","year":"1988","journal-title":"Exp Eye Res"},{"key":"R34-1-20210130","first-page":"47","article-title":"Ocular inflammatory effects of intravitreally injected tumor necrosis factor.","volume":"133","author":"Rosenbaum","year":"1988","journal-title":"Am J Pathol"},{"key":"R35-1-20210130","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0014-4835(95)80011-5","article-title":"Tumour necrosis factor induced uveitis in the lewis rat is associated with intraocular interleukin 6 production.","volume":"60","author":"De Vos","year":"1995","journal-title":"Exp Eye Res"},{"key":"R36-1-20210130","first-page":"2583","article-title":"IL-1 and TNF receptor \u2013deficient mice show decreased inflammation in an immune complex model of uveitis.","volume":"40","author":"Brito","year":"1999","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R37-1-20210130","first-page":"2408","article-title":"Tumor necrosis factor-a is not essential in endotoxin induced eye inflammation: studies in cytokine receptor deficient mice.","volume":"25","author":"Rosenbaum","year":"1998","journal-title":"J Rheumatol"},{"key":"R38-1-20210130","first-page":"2911","article-title":"The paradoxical effect of tumor necrosis alpha (TNF-a) in endotoxin-induced uveitis.","volume":"34","author":"Kasner","year":"1993","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R39-1-20210130","first-page":"299","article-title":"Failure to inhibit endotoxin\u2013 induced uveitis with antibodies that neutralize tumor necrosis factor.","volume":"5","author":"Rosenbaum","year":"1993","journal-title":"Reg Immunol"},{"key":"R40-1-20210130","first-page":"73","article-title":"Failure to inhibit endotoxin-induced uveitis with soluble TNF receptors.","volume":"6","author":"Rosenbaum","year":"1994","journal-title":"Reg Immunol"},{"key":"R41-1-20210130","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1046\/j.1365-2249.2000.01339.x","article-title":"Local bioactive tumour necrosis factor (TNF) in corneal allotransplantation.","volume":"122","author":"Rayner","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"R42-1-20210130","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0002-9440(10)63952-1","article-title":"Leukocyte-mediated endothelial cell injury and death in the diabetic retina.","volume":"158","author":"Joussen","year":"2001","journal-title":"Am J Pathol"},{"key":"R43-1-20210130","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1096\/fj.03-1476fje","article-title":"A central role for inflammation in the pathogenesis of diabetic retinopathy.","volume":"18","author":"Joussen","year":"2004","journal-title":"FASEB J"},{"key":"R45-1-20210130","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1023\/A:1009010628371","article-title":"Lipid hydroperoxide stimulates retinal neovascularization in rabbit retina through expression of tumor necrosis factor-alpha, vascular endothelial growth factor, and platelet-derived growth factors.","volume":"1","author":"Armstrong","year":"1998","journal-title":"Angiogenesis"},{"key":"R46-1-20210130","first-page":"260","article-title":"Regulation of matrix metalloproteinase expression by tumor necrosis factor in a murine model of retinal neovascularization.","volume":"43","author":"Majka","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R47-1-20210130","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0140-6736(01)06677-6","article-title":"Effect of infliximab on threatening panuveitis in Behcet's disease (letter).","volume":"358","author":"Munoz-Feranandez","year":"2001","journal-title":"Lancet"},{"key":"R48-1-20210130","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/1529-0131(200106)45:3<252::AID-ART257>3.0.CO;2-5","article-title":"Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease.","volume":"45","author":"Smith","year":"2001","journal-title":"Arthritis Care Res"},{"key":"R49-1-20210130","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/sj.eye.6701712","article-title":"Anti-TNF alpha therapy in chronic necrotizing scleritis resistant to standard immunomodulatory therapy in a patient with Wegener's granulomatosis.","volume":"19","author":"El-Shabrawi","year":"2005","journal-title":"Eye"},{"key":"R50-1-20210130","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1572-0241.2002.05514.x","article-title":"Treatment of acute uveitis associated with Crohn's disease and sacroiliitis with infliximab.","volume":"97","author":"Fries","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R51-1-20210130","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/03009740510026698","article-title":"Infliximab in the treatment of extra-intestinal manifestations of Crohn's disease.","volume":"34","author":"Rispo","year":"2005","journal-title":"Scand J Rheumatol"},{"key":"R52-1-20210130","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1016\/S0161-6420(02)01292-7","article-title":"Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leucocyte antigen B27-associated acute anterior uveitis.","volume":"109","author":"El-Shabrawi","year":"2002","journal-title":"Ophthalmology"},{"key":"R53-1-20210130","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1136\/ard.61.6.560","article-title":"Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behcet's disease.","volume":"61","author":"Triolo","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"R54-1-20210130","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1136\/ard.61.5.470","article-title":"Successful use of infliximab in a patient with treatment resistant spondyloarthropathy related uveitis.","volume":"61","author":"Kruithof","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"R55-1-20210130","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1001\/archneur.60.3.426","article-title":"The pathogenesis and treatment of optic disc swelling in neurosarcoidosis: a unique therapeutic response to infliximab.","volume":"60","author":"Katz","year":"2003","journal-title":"Arch Neurol"},{"key":"R56-1-20210130","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0161-6420(03)00406-8","article-title":"Infliximab in the treatment of refractory posterior uveitis.","volume":"110","author":"Joseph","year":"2003","journal-title":"Ophthalmology"},{"key":"R57-1-20210130","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-2474-4-19","article-title":"Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report.","volume":"4","author":"Gulli","year":"2003","journal-title":"BMC Musculoskel Disord"},{"key":"R58-1-20210130","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s00296-003-0308-1","article-title":"Therapeutic experience with infliximab in a patient with polyarticular juvenile idiopathic arthritis and uveitis.","volume":"23","author":"Mangge","year":"2003","journal-title":"Rheumatol Int"},{"key":"R59-1-20210130","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1378\/chest.124.5.2028","article-title":"Refractory sarcoidosis responding to infliximab.","volume":"124","author":"Roberts","year":"2003","journal-title":"Chest"},{"key":"R60-1-20210130","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0161-6420(03)00721-8","article-title":"Tumor necrosis factor-a blockade with infliximab for refractory uveitis and scleritis.","volume":"111","author":"Murphy","year":"2004","journal-title":"Ophthalmology"},{"key":"R61-1-20210130","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/112067210401400515","article-title":"Infliximab for the treatment of posterior uveitis with retinal neovascularization in Behcet disease.","volume":"14","author":"Giansanti","year":"2004","journal-title":"Eur J Ophthalmol"},{"key":"R62-1-20210130","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/ard.2002.004226","article-title":"Tumour necrosis factor-a inhibitor treatment for sarcoidosis refractory to conventional treatments. A report of five patients.","volume":"63","author":"Pritchard","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"R63-1-20210130","doi-asserted-by":"crossref","first-page":"404","DOI":"10.7326\/0003-4819-140-5-200403020-00025","article-title":"Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease.","volume":"140","author":"Sfikakis","year":"2004","journal-title":"Ann Intern Med"},{"key":"R64-1-20210130","first-page":"14","article-title":"Infliximab in refractory uveitis due to Behcet's disease.","volume":"22","author":"Wechsler","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"R65-1-20210130","first-page":"1362","article-title":"Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis.","volume":"31","author":"Ohno","year":"2004","journal-title":"J Rheumatol"},{"key":"R66-1-20210130","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.ajo.2004.06.077","article-title":"Treatment of recalcitrant idiopathic orbital inflammation (chronic orbital myositis) with infliximab.","volume":"138","author":"Garrity","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"R67-1-20210130","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.ajo.2004.04.066","article-title":"Infliximab for chronic cystoid macular edema associated with uveitis.","volume":"138","author":"Markomichelakis","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"R68-1-20210130","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ajo.2004.09.058","article-title":"Regression of neovascular age-related macular degeneration following infliximab therapy.","volume":"139","author":"Markomichelakis","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"R69-1-20210130","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5414\/CPP43007","article-title":"Infliximab in chronic ocular inflammation.","volume":"43","author":"Baughmann","year":"2005","journal-title":"Int J Clin Pharmacol Ther"},{"key":"R70-1-20210130","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1378\/chest.127.3.1064","article-title":"Treatment of sarcoidosis with infliximab.","volume":"127","author":"Doty","year":"2005","journal-title":"Chest"},{"key":"R71-1-20210130","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2337\/diacare.28.2.445","article-title":"Regression of sight-threatening macular edema in type 2 diabetes following treatment with the anti-tumor necrosis factor monoclonal antibody infliximab.","volume":"28","author":"Sfikakis","year":"2005","journal-title":"Diabetes Care"},{"key":"R72-1-20210130","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/ard.2004.025882","article-title":"Therapeutic use of Infliximab in sight-threatening uveitis: retrospective analysis of efficacy, safety and limiting factors.","volume":"64","author":"Bodaghi","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R73-1-20210130","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/bjo.2003.037192","article-title":"Anti-TNF-alpha therapy for sight threatening uveitis.","volume":"89","author":"Lindstedt","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"R74-1-20210130","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0755-4982(05)84079-5","article-title":"Infliximab in the treatment of posterior uveitis in Behcet's disease. Long term follow up in four patients.","volume":"34","author":"Lanthier","year":"2005","journal-title":"Presse Med"},{"key":"R75-1-20210130","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/archopht.123.7.903","article-title":"A prospective trial of infliximab therapy for refractory uveitis.","volume":"123","author":"Suhler","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"R76-1-20210130","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/rheumatology\/keh445","article-title":"A case of Beh\u00e7et's disease with scleromalacia perforans.","volume":"44","author":"Sakellariou","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"R77-1-20210130","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/01.rhu.0000173218.28013.3e","article-title":"Infliximab-responsive uveitis and vasculitis in a patient with Takayasu arteritis.","volume":"11","author":"Jolly","year":"2005","journal-title":"J Clin Rheumatol"},{"key":"R78-1-20210130","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.eye.6701689","article-title":"Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab).","volume":"19","author":"Benites-Del-Castillo","year":"2005","journal-title":"Eye"},{"key":"R79-1-20210130","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/art.21231","article-title":"Efficacy of Infliximab in the treatment of uveitis that is refractory to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Beh\u00e7et's disease. An open-label trial.","volume":"52","author":"Tugal-Tutkun","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R80-1-20210130","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1442-9071.2005.01062.x","article-title":"Infliximab for juvenile idiopathic arthritis\u2013associated uveitis.","volume":"33","author":"Richards","year":"2005","journal-title":"Clin Exp Ophthalmol"},{"key":"R81-1-20210130","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ophtha.2005.09.037","article-title":"Retrospective case review of pediatric patients with uveitis treated with infliximab.","volume":"113","author":"Rajaraman","year":"2006","journal-title":"Ophthalmology"},{"key":"R82-1-20210130","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/rheumatology\/kel030","article-title":"Tumour necrosis alpha inhibitors in the treatment of childhood uveitis.","volume":"45","author":"Saurenmann","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"R83-1-20210130","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/1529-0131(200106)44:6<1411::AID-ART235>3.0.CO;2-O","article-title":"Etanercept therapy in children with treatment-resistant uveitis.","volume":"45","author":"Reiff","year":"2001","journal-title":"Arthritis Rheum"},{"key":"R84-1-20210130","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/archopht.121.4.437","article-title":"Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate.","volume":"121","author":"Foster","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"R85-1-20210130","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/sj.eye.6701827","article-title":"The effect of etanercept on Graves' ophthalmopathy: a pilot study.","volume":"20","author":"Paridaens","year":"2006","journal-title":"Eye"},{"key":"R86-1-20210130","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/art.20904","article-title":"A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis.","volume":"53","author":"Smith","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R87-1-20210130","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S0012-3692(15)50471-6","article-title":"Etanercept for refractory ocular sarcoidosis: results of double-blind, randomized trial.","volume":"128","author":"Baughman","year":"2005","journal-title":"Chest"},{"key":"R88-1-20210130","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/art.503","article-title":"Management of uveitis.","volume":"46","author":"Smith","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R89-1-20210130","article-title":"Uveitis: Fundamentals and Clinical Practice. 3rd ed.","author":"Nussenblatt","year":"2004"},{"key":"R90-1-20210130","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0002-9394(00)00659-0","article-title":"Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: Recommendations of an expert panel.","volume":"130","author":"Jabs","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"R91-1-20210130","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0049-0172(98)80001-2","article-title":"Behcet's disease.","volume":"27","author":"Kaklamani","year":"1998","journal-title":"Semin Arthritis Rheum"},{"key":"R92-1-20210130","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1053\/sarh.2001.19819","article-title":"Treatment of Behcet's disease: an update.","volume":"30","author":"Kaklamani","year":"2001","journal-title":"Semin Arthritis Rheum"},{"key":"R93-1-20210130","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ajo.2004.03.022","article-title":"Uveitis in Behcet's disease: an analysis of 880 patients.","volume":"138","author":"Tugal-Tutkun","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"R94-1-20210130","first-page":"128","article-title":"Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Behcet's disease soluble TNFR-75 as a biologic marker of disease activity.","volume":"24","author":"Turan","year":"1997","journal-title":"J Rheumatol"},{"key":"R95-1-20210130","first-page":"708","article-title":"High levels of TNF-a in the aqueous humor in patients suffering from Adamantiades\u2013Beh\u00e7et's disease: preliminary results.","volume":"42","author":"Chronopoulou","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R96-1-20210130","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/0-306-48382-3_52","article-title":"Serum levels of soluble TNF receptor-II (p75), circulating \u03b3\u0394 T-cells, and Adamantiades-Behcet's disease activity.","volume":"528","author":"Elezoglou","year":"2003","journal-title":"Adv Clin Exp Biol"},{"key":"R97-1-20210130","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/0-306-48382-3_111","article-title":"Successful long-term treatment of refractory Adamantiades-Behcet's disease with Infliximab.","volume":"528","author":"Katsiari","year":"2003","journal-title":"Adv Clin Exp Biol"},{"key":"R98-1-20210130","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/art.10302","article-title":"The relationship of serum Infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial.","volume":"46","author":"Clair","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R99-1-20210130","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of Infliximab in Crohn's disease.","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"R100-1-20210130","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0039-6257(03)00084-5","article-title":"Recent advances in uveitis of juvenile idiopathic arthritis.","volume":"48","author":"Kotaniemi","year":"2003","journal-title":"Surv Ophthalmol"},{"key":"R101-1-20210130","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1093\/rheumatology\/keh658","article-title":"Etanercept and uveitis in patients with juvenile idiopathic arthritis.","volume":"44","author":"Schmerling","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"R102-1-20210130","first-page":"143","article-title":"Anti-TNF therapy for eye involvement in spondyloarthropathy.","volume":"20","author":"Rosenbaum","year":"2002","journal-title":"Clin Exp Rheumatol"},{"key":"R103-1-20210130","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/art.21197","article-title":"Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-TNF agents infliximab and etanercept.","volume":"52","author":"Braun","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R104-1-20210130","first-page":"36","article-title":"Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis.","volume":"115","author":"Baughman","year":"1990","journal-title":"J Lab Clin Med"},{"key":"R105-1-20210130","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/0091-6749(93)90352-G","article-title":"Increased secretion of tumor necrosis factor\u2013alpha, interleukin-1-beta, and interleukin-6 by alveolar macrophages from patients with sarcoidosis.","volume":"91","author":"Steffen","year":"1993","journal-title":"J Allergy Clin Immunol"},{"key":"R106-1-20210130","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1164\/ajrccm.152.3.7663784","article-title":"Alveolar macrophage TNF-a release and BAL cell phenotypes in sarcoidosis.","volume":"152","author":"Zheng","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"R107-1-20210130","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1378\/chest.124.1.177","article-title":"Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis.","volume":"124","author":"Utz","year":"2003","journal-title":"Chest"},{"key":"R108-1-20210130","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1053\/gast.2001.29035","article-title":"Transmembrane TNF-a, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease.","volume":"121","author":"van Deventer","year":"2001","journal-title":"Gastroenterology"},{"key":"R109-1-20210130","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/ard.61.suppl_2.ii51","article-title":"Behcet's disease: a new target for anti- tumour necrosis factor treatment.","volume":"61","author":"Sfikakis","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"R110-1-20210130","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1124\/jpet.301.2.418","article-title":"Binding and functional comparisons of two types of tumor necrosis factor antagonists.","volume":"301","author":"Scallon","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"R111-1-20210130","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1001\/archopht.122.6.845","article-title":"Neutralizing tumor necrosis factor activity leads to remission in patients with refractory non-infectious posterior uveitis.","volume":"122","author":"Murphy","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"R112-1-20210130","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1167\/iovs.03-0659","article-title":"Anti-TNF-a therapy modulates the phenotype of peripheral blood CD 4 T cells in patients with posterior segment intraocular inflammation.","volume":"45","author":"Greiner","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R113-1-20210130","first-page":"136","article-title":"Orbital myositis in a rheumatoid arthritis patient during etanercept treatment.","volume":"21","author":"Caramaschi","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"R114-1-20210130","first-page":"553","article-title":"Ocular Infection and Immunity.","author":"Tessler","year":"1966"},{"key":"R115-1-20210130","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.2337\/diacare.26.9.2653","article-title":"Diabetic retinopathy and diabetic macular edema.","volume":"26","author":"Ciulla","year":"2003","journal-title":"Diabetes Care"},{"key":"R116-1-20210130","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/08820539909069541","article-title":"The pathogenesis of edema in diabetic maculopathy.","volume":"14","author":"Antcliff","year":"1999","journal-title":"Semin Ophthalmol"},{"key":"R117-1-20210130","first-page":"134","article-title":"TNF in the vitreous body increases in neovascular eye diseases and PDR.","volume":"90","author":"Pragner","year":"1995","journal-title":"Med Klin"},{"key":"R118-1-20210130","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/bjo.80.2.168","article-title":"Distribution of TNF and its reactive vascular adhesion molecules in fibrovascular membranes of PDR.","volume":"80","author":"Limb","year":"1996","journal-title":"Br J Ophthalmol"},{"key":"R119-1-20210130","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/bjo.83.11.1296","article-title":"Detection of cytokine mRNA production in infiltrating cells in proliferative vitreoretinopathy using reverse transcription polymerase chain reaction.","volume":"83","author":"El-Ghrably","year":"1999","journal-title":"Br J Ophthalmol"},{"key":"R120-1-20210130","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1046\/j.1365-2249.1999.01067.x","article-title":"Platelet expression of tumour necrosis factor-alpha (TNF-alpha), TNF receptors and intercellular adhesion molecule-1(ICAM-1) in patients with proliferative diabetic retinopathy.","volume":"118","author":"Limb","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"R121-1-20210130","first-page":"1586","article-title":"Soluble TNF receptors in vitreoretinal proliferative disease.","volume":"42","author":"Limb","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R122-1-20210130","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/sj\/eye\/6700095","article-title":"Comparison of serum NO, TNF-alpha, IL-beta, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus.","volume":"16","author":"Doganay","year":"2002","journal-title":"Eye"},{"key":"R123-1-20210130","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0039-6257(03)00030-4","article-title":"Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies.","volume":"48","author":"Ambati","year":"2003","journal-title":"Surv Ophthalmol"},{"key":"R124-1-20210130","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1001\/archopht.123.6.774","article-title":"Progression of age-related macular degermation: prospective assessment of C-reactive protein, interleukin-6, and other cardiovascular markers.","volume":"123","author":"Seddon","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"R125-1-20210130","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration.","volume":"351","author":"Gragoudas","year":"2004","journal-title":"N Engl J Med"},{"key":"R126-1-20210130","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1002\/art.20181","article-title":"Antiangiogenic effects of anti-tumor necrosis factor alpha therapy with infliximab in psoriatic arthritis.","volume":"50","author":"Canete","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R127-1-20210130","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s00296-005-0619-5","article-title":"Anti-TNF-alpha antibody infliximab and glucocorticoids reduce serum vascular endothelial growth factor levels in patients with rheumatoid arthritis.","volume":"26","author":"Strunk","year":"2006","journal-title":"Rheumatol Int"},{"key":"R128-1-20210130","first-page":"S1114","article-title":"The role of TNF in health and disease.","volume":"26","author":"Beutler","year":"1999","journal-title":"J Rheumatol"},{"key":"R129-1-20210130","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/art.10758","article-title":"Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor a-neutralizing agents.","volume":"48","author":"Slifman","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R130-1-20210130","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1086\/502250","article-title":"Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody. A possible healthcare associated case?","volume":"24","author":"De Rosa","year":"2003","journal-title":"Infect Control Hosp Epidemiol"},{"key":"R131-1-20210130","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/rheumatology\/41.8.951","article-title":"Pneumocystis carinii pneumonia following a second infusion of infliximab.","volume":"41","author":"Tai","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"R132-1-20210130","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1002\/art.10583","article-title":"Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept.","volume":"46","author":"Lee","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R133-1-20210130","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor a-neutralizing agent.","volume":"345","author":"Keane","year":"1999","journal-title":"N Engl J Med"},{"key":"R134-1-20210130","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1002\/art.11301","article-title":"Infections and anti-tumor necrosis factor a therapy.","volume":"48","author":"Ellerin","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R135-1-20210130","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infections diseases associated with TNF antagonists [correction in Clin Infect Dis 2004;39:1254\u20131255].","volume":"38","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R136-1-20210130","first-page":"683","article-title":"Tuberculosis associated with blocking agents against tumor necrosis factor-alpha, California 2002-2203","volume":"53","year":"2004","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R137-1-20210130","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1002\/art.11137","article-title":"Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.","volume":"48","author":"Gomez Reino","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R138-1-20210130","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0140-6736(02)07714-0","article-title":"Drug-induced systemic lupus erythematosus associated with etanercept therapy.","volume":"359","author":"Shakoor","year":"2002","journal-title":"Lancet"},{"key":"R139-1-20210130","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1002\/art.21233","article-title":"Psoriasis induced by anti-Tumor necrosis factor therapy: a paradoxical adverse reaction.","volume":"52","author":"Sfikakis","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R141-1-20210130","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1002\/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D","article-title":"Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to TNF alpha: findings in open-label and randomized placebo-controlled trials.","volume":"43","author":"Charles","year":"2000","journal-title":"Arthritis Rheum"},{"key":"R142-1-20210130","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/WNL.53.3.457","article-title":"TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS\/MRI Analysis Group.","volume":"53","year":"1999","journal-title":"Neurology"},{"key":"R143-1-20210130","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","article-title":"Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.","volume":"44","author":"Mohan","year":"2001","journal-title":"Arthritis Rheum"},{"key":"R144-1-20210130","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1002\/1529-0131(200109)44:9<1977::AID-ART345>3.0.CO;2-6","article-title":"Demyelinating and neurologic events reported in association with TNF-a antagonism: by what mechanisms could TNF-a antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?","volume":"44","author":"Robinson","year":"2001","journal-title":"Arthritis Rheum"},{"key":"R145-1-20210130","first-page":"985","article-title":"Retrobulbar optic neuritis associated with infliximab.","volume":"120","author":"Foroozan","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"R146-1-20210130","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/rheumatology\/keh468","article-title":"Optic neuritis associated with etanercept therapy in two patients with extended oligoarticular juvenile idiopathic arthritis.","volume":"44","author":"Tauber","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"R147-1-20210130","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1345\/aph.1G279","article-title":"Optic neuritis with concurrent etanercept and isoniazid therapy.","volume":"39","author":"Noguera-Pons","year":"2005","journal-title":"Ann Pharmacother"},{"key":"R148-1-20210130","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0161-6420(99)90122-7","article-title":"Pars planitis: clinical features and class II HLA associations.","volume":"106","author":"Raja","year":"1999","journal-title":"Ophthalmology"},{"key":"R149-1-20210130","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1067\/mjd.2001.117725","article-title":"Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy.","volume":"45","author":"Smith","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"R150-1-20210130","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1002\/art.10679","article-title":"Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration.","volume":"46","author":"Brown","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R151-1-20210130","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1002\/art.20312","article-title":"Anti-tumor necrosis factor therapy and the risk of lymphoma in rheumatoid arthritis: no clear answer.","volume":"50","author":"Symmons","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R152-1-20210130","doi-asserted-by":"crossref","first-page":"807","DOI":"10.7326\/0003-4819-138-10-200305200-00008","article-title":"Case reports of heart failure after therapy with a tumor necrosis factor antagonist.","volume":"138","author":"Kwon","year":"2003","journal-title":"Ann Intern Med"},{"key":"R153-1-20210130","first-page":"1196","article-title":"All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practise Research Database.","volume":"30","author":"Watson","year":"2003","journal-title":"J Rheumatol"},{"key":"R154-1-20210130","first-page":"1241","article-title":"Blind insight: eyeing anti-tumor necrosis factor treatment in uveitis associated with Beh\u00e7et's disease.","volume":"31","author":"Rosenbaum","year":"2004","journal-title":"J Rheumatol"},{"key":"R155-1-20210130","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/sj.eye.6701792","article-title":"Anti-TNF-a therapy for uveitis. Behcet's and beyond.","volume":"19","author":"Murray","year":"2005","journal-title":"Eye"},{"key":"R156-1-20210130","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/archopht.123.7.1000","article-title":"Treating intraocular inflammatory disease in the 21st century.","volume":"123","author":"Nussenblatt","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"R157-1-20210130","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1007\/s00417-004-0895-x","article-title":"Pharmacokinetics and safety of intravitreally delivered etanercept.","volume":"242","author":"Fauser","year":"2004","journal-title":"Graefes Arch Clin Exp Ophthalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00006982-200704000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T09:37:17Z","timestamp":1736933837000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006982-200704000-00001"}},"subtitle":["Preliminary Evidence for an Emerging Approach in the Treatment of Ocular Inflammation"],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":155,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/maj.0b013e3180318fbc","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}